ORCID

We notice you are using a browser that our site does not support. Some features on this site may not work correctly. We recommend that you upgrade to a supported browser.

Activities

Collapse all

Bone marrow vascular microenvironment combination RNAi-bortezomib nanotherapy for multiple myeloma

2023-01-01 to 2026-12-31 | Grant

American Cancer Society (Atlanta, US)

DOI: 10.53354/pc.gr.158358

GRANT_NUMBER:

RSG-22-122-01-ET

Show more detail

Source:

check_circle

American Cancer Society - ProposalCentral

How many people are using ORCID?

https://orcid.org/0000-0002-3628-2244

Activities

Funding (1)

Bone marrow vascular microenvironment combination RNAi-bortezomib nanotherapy for multiple myeloma

https://orcid.org/0000-0002-3628-2244

Personal information

Activities

Funding (1)

Bone marrow vascular microenvironment combination RNAi-bortezomib nanotherapy for multiple myeloma